J
J.-M. Bayas
Publications - 5
Citations - 381
J.-M. Bayas is an academic researcher. The author has contributed to research in topics: Booster dose & Hepatitis B. The author has an hindex of 4, co-authored 5 publications receiving 364 citations.
Papers
More filters
Journal ArticleDOI
Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients
Norella Kong Chiew Tong,Jiri Beran,Swee Ann Kee,Jose Luis Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,J R de Juanes,P. Arrazola,Francisco Calbo-Torrecillas,Eduardo López de Novales,Virginie Hamtiaux,Marc Lievens,Michel Stoffel +13 more
TL;DR: The improved immunogenicity profile and clinically acceptable reactogenicity of HB-AS04 vaccine are of key importance to provide a more rapid, enhanced, and longer seroprotection to these immunocompromised patients at risk for HB infection.
Journal ArticleDOI
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients
Norella C T Kong,Jiri Beran,S. A. Kee,J. L. Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,F. Calbo-Torrecillas,E. Lopez De Novales,Karthik Srinivasa,Michel Stoffel,Bernard Hoet +11 more
TL;DR: In this paper, the authors evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in prehemodialysis and hemodialysis patients.
Journal Article
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Commentary
J. K. Unger,H. Peters,Norella C T Kong,Jiri Beran,S. A. Kee,J. L. Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,F. Calbo-Torrecillas,E. Lopez De Novales,Karthik Srinivasa,Michel Stoffel,Bernard Hoet +13 more
TL;DR: In this population of prehemodialysis and hemodialysis patients, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV -AS04 or standard hepatitis B vaccine priming.
Journal ArticleDOI
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
Frederik Nevens,Jane N. Zuckerman,Andrew K. Burroughs,Maria-Christina Jung,J.-M. Bayas,Birgit Kallinowski,Enrique Fraga Rivas,Christophe Duvoux,Peter Neuhaus,Faouzi Saliba,Maria Buti,Jean-Pierre Zarski,F. Pons,Claire Vanlemmens,Virginie Hamtiaux,Michel Stoffel +15 more
TL;DR: An improved antibody response was observed in liver transplant candidates with 3 doses of HB‐AS04, as compared to 4 double doses of a comparator, and Liver transplant candidates could benefit from the use of this experimental adjuvanted HB vaccine to further increase their protection against HB infection.
Journal ArticleDOI
Immunogenicity and safety of a novel adjuvanted hepatitis B candidate vaccine in liver transplant patients
Frederik Nevens,Jane N. Zuckerman,A.K. Burroughs,Maria-Christina Jung,J.-M. Bayas,Birgit Kallinowski,M. de la Mata,Christophe Duvoux,Peter Neuhaus,Faouzi Saliba,Maria Buti,JP Zarski,F. Pons,Claire Vanlemmens,Hamtiaux,Michel Stoffel +15 more
TL;DR: The immunogenicity of primary vaccination with 2 doses of an experimental adjuvanted HB vaccine (adjuvant system 04 containing aluminium andmonophosphoryl lipid A [HB-AS04) to that of 3 double doses of a licensed HB vaccine in 93 liver transplant candidates was compared.